Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SolasCure Enrols First Patient in Phase 2 Trial for Aurase Wound Gel
Details : Aurase Wound Gel is a hydrogel releasing Tarumase, a recombinant enzyme that selectively targets fibrin, collagen & elastin in wounds to promote healing through debridement.
Product Name : Aurase Wound Gel
Product Type : Enzyme
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial of Aurase Wound Gel
Details : Aurase is an enzyme analogue large molecule drug candidate, which is currently being evaluated for the treatment of patients suffering from chronic venous leg ulcer.
Product Name : Aurase
Product Type : Enzyme
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : Tarumase
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable